Press Releases

Presentation and Live Webcast to be Held June 4, 2024, at 10:15 am ET

THE WOODLANDS, Texas, May 29, 2024 (GLOBE NEWSWIRE) -- Howard Hughes Holdings Inc. (NYSE: HHH) announced today that Chief Financial Officer Carlos Olea will participate in a presentation moderated by Alex Goldfarb from Piper Sandler at NAREIT's REITweek 2024 Investor Conference in New York City on Tuesday, June 4, 2024, at 10:15 am ET.

HHH's live presentation will be accessible via audio webcast... (continue reading...)

TORONTO, May 29, 2024 (GLOBE NEWSWIRE) -- Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) (“Red Pine” or the “Company”) is pleased to announce the most recent assay results from 14 drill holes representing 4,105 metres (“m”) of drilling from the 2022-2024 resource expansion program at the Wawa Gold Project. Since the resource expansion drilling program began in 2021, Red Pine has now completed approximately 67,000 m of additional drilling in the... (continue reading...)

LONDON, May 29, 2024 /PRNewswire/ -- The Over-The-Top (OTT) video streaming market in the Middle East and North Africa (MENA) region experienced robust growth in 2023, with Omdia data reporting a 13% increase across the region and revenues exceeding $1 billion. Leading in this dynamic market are Shahid and StarzPlay, which dominate with significant market shares and innovative strategies.

... (continue reading...)

Acceptance based on results from the pivotal Phase 3 CCTG IND.227/KEYNOTE-483 trial, which demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA)... (continue reading...)

-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated preclinical monotherapy efficacy profile, the potential for broader therapeutic margin than other Trop-2 ADCs currently in development, and synergistic affects when combined with anti-PD1 therapy

-Biohaven also entered into a clinical supply agreement with Regeneron to study the combination of BHV-1510 with Regeneron's... (continue reading...)